RANI — Rani Therapeutics Holdings Balance Sheet
0.000.00%
- $117.86m
- $121.30m
- $1.03m
Annual balance sheet for Rani Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 73.1 | 117 | 98.5 | 48.5 | 27.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.72 | — | — | — | 0.428 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 74.9 | 120 | 101 | 50.8 | 29.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.47 | 4.61 | 7.1 | 6.82 | 6.64 |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 79.4 | 124 | 108 | 57.9 | 36.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.31 | 2.64 | 4.82 | 7.99 | 19.9 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.04 | 76.8 | 71.2 | 45 | 34.6 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 71.4 | 47.4 | 36.9 | 12.9 | 1.99 |
| Total Liabilities & Shareholders' Equity | 79.4 | 124 | 108 | 57.9 | 36.6 |
| Total Common Shares Outstanding |